Ticker >

Mankind Pharma share price

Mankind Pharma Ltd.

NSE: MANKIND BSE: 543904 SECTOR: Pharmaceuticals & Drugs  44k   131   22

1795.30
+30.85 (1.75%)
NSE: 29 Sep 03:57 PM

Price Summary

Today's High

₹ 1845

Today's Low

₹ 1763.95

52 Week High

₹ 1949

52 Week Low

₹ 1242

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

71917.64 Cr.

Enterprise Value

71762.49 Cr.

No. of Shares

40.06 Cr.

P/E

57.61

P/B

5.75

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  312.43

CASH

155.15 Cr.

DEBT

0 Cr.

Promoter Holding

76.5 %

EPS (TTM)

₹  31.16

Sales Growth

8.56%

ROE

17.43 %

ROCE

21.2%

Profit Growth

-10.16 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year8.56%
3 Year19.23%
5 Year15.62%

Profit Growth

1 Year-10.16%
3 Year9.21%
5 Year12.45%

ROE%

1 Year17.43%
3 Year22.65%
5 Year22.69%

ROCE %

1 Year21.2%
3 Year29.07%
5 Year29.25%

Debt/Equity

0

Price to Cash Flow

39.98

Interest Cover Ratio

56.3624119705837

CFO/PAT (5 Yr. Avg.)

0.981829882711496

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2023 76.5 0
Mar 2023 76.5 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 19.234021526329% for the Past 3 years.
  • The company has significantly decreased its debt by 683.6619 Cr.
  • Company has been maintaining healthy ROE of 22.6458826240257% over the past 3 years.
  • Company has been maintaining healthy ROCE of 29.0675389309682% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 56.3624119705837.
  • The Company has been maintaining an effective average operating margins of 22.5729111686494% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -40.2780747748101 days.
  • Company has a healthy liquidity position with current ratio of 2.47604430231229.
  • The company has a high promoter holding of 76.5%.
  • Promoter stake has increased from 0% to 76.5% in the last 1 quarter.

 Limitations

  • The company has shown a poor profit growth of 9.21406976263837% for the Past 3 years.
  • The company is trading at a high EV/EBITDA of 38.5223.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2023 Jun 2023
Net Sales 1872.12 2300.21
Total Expenditure 1490.96 1760.74
Operating Profit 381.16 539.47
Other Income 42.46 57.44
Interest 0.89 1.97
Depreciation 67.3 68.54
Exceptional Items 0 0
Profit Before Tax 355.43 526.39
Tax 74.45 117.11
Profit After Tax 280.99 409.28
Adjusted EPS (Rs) 7.01 10.22

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 3829.06 4794.41 5523.18 7486.22 8127.15
Total Expenditure 3124.1 3550.47 4151.05 5647.73 6429.29
Operating Profit 704.96 1243.94 1372.13 1838.49 1697.86
Other Income 64.33 93.85 154.5 203.81 162.78
Interest 39.61 11.1 8.23 47.54 28.23
Depreciation 38.39 61.77 78.19 123.33 269.58
Exceptional Items 0 0 0 0 0
Profit Before Tax 691.3 1264.92 1440.21 1871.44 1562.84
Tax 177.26 306.7 355.83 482.01 314.58
Net Profit 514.04 958.23 1084.37 1389.42 1248.26
Adjusted EPS (Rs.) 12.83 23.92 27.07 34.68 31.16

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 40.06 40.06 40.06 40.06 40.06
Total Reserves 3024.76 3611.39 4694.21 6500.39 7743.85
Borrowings 0 0 0 0 0
Other N/C liabilities 60.6 42.84 54.11 126.98 168.12
Current liabilities 725.15 815.77 1078.91 2271.27 1419.09
Total Liabilities 3850.57 4510.06 5867.29 8938.7 9371.12
Assets
Net Block 767.52 939.25 981.95 2921.3 3136.89
Capital WIP 210.04 143.93 165.51 355.28 437.83
Intangible WIP 1.07 3.69 0.06 31.28 56.95
Investments 1394.24 1395.02 1500.86 1657.08 2040.76
Loans & Advances 92.8 77.6 115.59 146.3 148.86
Other N/C Assets 2.61 1.96 13.34 14.45 36.1
Current Assets 1382.29 1948.6 3089.98 3813.01 3513.72
Total Assets 3850.57 4510.06 5867.29 8938.7 9371.12
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 691.3 1264.92 1440.21 1871.44 1562.84
Adjustment 32.07 137.23 96.74 -4.16 227
Changes in Assets & Liabilities 59.1 -168.42 -156.19 -585.61 294.21
Tax Paid -245.94 -274.12 -397.38 -460.22 -285.06
Operating Cash Flow 536.52 959.61 983.38 821.44 1798.99
Investing Cash Flow -305.58 -395.68 -1127.16 -1360.27 -1040.61
Financing Cash Flow -239.81 -558.91 88.87 578.63 -710.41
Net Cash Flow -8.87 5.02 -54.91 39.81 47.96

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023%
promoters 76.50 76.50
arjun juneja 2.64 2.64
chanakya juneja 0.97 0.97
eklavya juneja 0.97 0.97
mishka arora - 0.74
poonam juneja 2.64 2.64
prem sheetal family trust... 15.42 15.42
puja juneja 3.45 3.45
rajeev juneja 1.62 1.62
rajeev juneja family trus... - 19.95
ramesh juneja 1.71 1.71
ramesh juneja family trus... - 20.81
ria chopra juneja 0.32 0.32
sheetal arora 5.27 5.27
mishka arora 0.74 -
rajeev juneja family trus... 19.95 -
ramesh juneja family trus... 20.81 -
PARTICULARS Mar 2023% Jun 2023%
investors 23.50 23.50
beige limited 7.46 7.46
cairnhill cipef limited 1.74 1.74
hema cipef (i) limited 3.63 3.63

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

  • PresentationQ4FY23 31 May 2023

Mankind Pharma Stock Price Analysis and Quick Research Report. Is Mankind Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Mankind Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 1798.9871 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Mankind Pharma has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Mankind Pharma , the EPS growth was -10.1601287026519 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Mankind Pharma has OPM of 20.8912328612189 % which is a good sign for profitability.
     
  • ROE: Mankind Pharma have a average ROE of 17.4285318016169 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Last Updated on:
Brief about Mankind Pharma
X